

CURRICULUM VITAE

Date updated: 4/9/2012

PERSONAL INFORMATION:

Name: Matthew L. Stoll
Citizenship: U.S.A.
Foreign languages: None
Home address: 2883 Acton Road / Apt H / Vestavia AL 35243
Phone: (214) 683-6003

RANK / TITLE: Assistant Professor, Division of Pediatric Rheumatology 2011
Department: Pediatrics
Business address: University of Alabama at Birmingham
1601 4th Ave South
Birmingham, AL 35233
Phone: (205) 939-9438

HOSPITAL AND OTHER (NON-ACADEMIC) APPOINTMENTS:

University of Alabama at Birmingham (Birmingham, AL) 2011 – present
Childrens Medical Center (Dallas, TX) 2007 – 2011
Texas Scottish Rite Hospital for Children 2007 – 2011

EDUCATION:

Wesleyan University (Middletown, CT) B.A. in mol. biol. & biochem. 1994
Graduated Phi Beta Kappa
SUNY Upstate Medical University (Syracuse, NY) M.D., Ph.D. (immunology) 2001
UT Southwestern Medical Center (Dallas, TX) M.S.C.S. 2011

LICENSURE:

New York (229888), inactive
Massachusetts (220256), inactive
Texas (M8363), inactive
Alabama (30926), active

BOARD CERTIFICATION:

2004 American Board of Pediatrics: General Pediatrics
2009 American Board of Pediatrics: Pediatric Rheumatology

POST-DOCTORAL TRAINING

2001 – 2004 Residency in pediatrics, Long Island Jewish Medical Center
2004 – 2007 Fellowship in pediatric rheumatology, Childrens Hospital Boston

ACADEMIC APPOINTMENTS:

2011 – present Assistant Professor, Department of Pediatrics, UAB
2008 – 2011 Assistant Professor, Department of Pediatrics, UTSW

Matthew Stoll MD, PhD

2007 – 2008 Instructor, Department of Pediatrics, UTSW

AWARDS / HONORS:

07/2004 Farley Fellowship Award (Childrens Hospital Boston; MA)
09/2000 Alpha Omega Alpha (SUNY Upstate Medical University; Syracuse, NY)
04/1994 Phi Beta Kappa (Wesleyan University; Middletown, CT)

PROFESSIONAL SOCIETIES:

2011 Alabama Society for Rheumatic Diseases
2010 Pediatric Rheumatology Collaborative Study Group
2007 American College of Rheumatology
2007 Childhood Arthritis and Rheumatology Research Alliance

UNIVERSITY ACTIVITIES:

(UT Southwestern Medical Center)

1. Rheumatology Epic liason (2007 – 2011)

(University of Alabama at Birmingham)

2. Graduate Student Research Day, judge (2012)

Clinical activities

1. Pediatric rheumatology clinic: three half-days per week.
2. Pediatric rheumatology consult service: 14 weeks per year

EDITORIAL BOARD MEMBERSHIPS

Ad hoc reviewer for following journals
Arthritis Care and Research
Arthritis Research and Therapy
Clinical and Experimental Immunology
Journal of Rheumatology
Pediatrics

MAJOR RESEARCH INTERESTS:

My major research interest is the link between mucosal immunity and spondyloarthritis. Specifically, I am looking at humoral responses to enteric organisms and the nature of the fecal flora in children with juvenile spondyloarthritis.

TEACHING EXPERIENCE:

Classroom instruction

Matthew Stoll MD,PhD

Fall 2011: Introduction to Clinical Medicine - I

Presentations

03/28/2012: Collagen vascular diseases. Pediatric residents board review, University of Alabama in Birmingham

10/13/2011: Juvenile idiopathic arthritis. Rheumatology grand rounds, University of Alabama in Birmingham

4/29/2011: Antibody testing in the evaluation of rheumatic diseases. 43rd Annual Kenneth C Haltalin Pediatrics for the Practitioner conference, Richardson TX.

12/7/2010: Mucosal immunity in and outcome of spondyloarthritis Rheumatology grand rounds, University of Alabama in Birmingham.

9/30/2010: Kids get spondyloarthritis, too! Rheumatology grand rounds, UTSW.

8/18/2010: Gut inflammation and arthritis. Gastroenterology noon conference, UTSW.

4/9/2010: Clinical research in pediatrics. Rheumatology fellow's conference, UTSW.

1/14/2010: Pediatric connective tissue diseases. Regional X Medical Conference for School-based PTs and OTs. Texas Scottish Rite Hospital.

1/6/2009: Sub-clinical gut inflammation in juvenile spondylarthritis. Department of Pediatrics Research Conference, UT Southwestern Medical Center

12/18/2008: Juvenile spondylarthritis. Rheumatology grand rounds, UT Southwestern Medical Center

5/29/2008: The risk of hospitalized infections in patients with rheumatoid arthritis. Rheumatology journal club, UT Southwestern Medical Center.

4/15/2008: Subgroups within oligo-articular JPsA and JIA: a clinical and gene expression analysis. Department of Pediatrics Research Conference, UT Southwestern Medical Center

1/24/2008: Pain syndromes. Physical therapy inservice, Texas Scottish Rite Hospital for Children's Medical Center Dallas

4/13/2007: Bone marrow B-lineage cells in RA patients treated with rituximab. Pediatric rheumatology grand rounds, Childrens Hospital Boston.

12/15/2006: Role of aspirin in the prevention of thrombotic events in anti-phospholipid antibody-positive patients. Pediatric rheumatology grand rounds, Childrens Hospital Boston.

GRANT SUPPORT:

Current

UAB School of Medicine: Immunology, Autoimmunity, and Transplant Strategic Effort

Autoimmunity against enteric antigens in juvenile spondyloarthritis

Award dates: 12/5/2011 – 11/30/2012

Role: Principal investigator

Previous

1 KL2 RR024983-01

Principal Investigator: Packer, Milton

Project Title: North and Central Texas Clinical and Translational Science Initiative (KL2)

Award Dates: 07/01/08 – present

Matthew Stoll MD,PhD

Role: Clinical Sciences Trainee

5 KL2 RR024983-02

Principal investigator: Packer, Milton

Award dates: 6/1/08 – 5/31/09

Role: pilot-award recipient PI

NIH/NCRR

Subgroups of juvenile psoriatic arthritis: a clinical and gene expression analysis

Goals: To understand age-based subgroups of juvenile psoriatic arthritis, and to understand potential differences between early-onset juvenile psoriatic arthritis and juvenile idiopathic arthritis

UL1 RR024982-01 Milton Packer (PI)

Award dates: 9/17/07 – 6/30/08

North and Central Texas Clinical and Translational Science Initiative (UL1)

Awardee: UT Southwestern Medical Center

Role: Clinical Sciences Trainee

T32-AI007512 Raif Geha (PI)

Award dates: 7/1/05 – 6/30/07

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32)Molecular Basis of Allergic and Immunologic Disease

Awardee: Childrens Hospital Boston

Role: Trainee.

BIBLIOGRAPHY:

Manuscripts already published

1. **Stoll ML** and Gavalchin J. Systemic Lupus Erythematosus—messages from experimental models. *Rheumatology* 2000; 39: 18-27.
2. Price K, Knupp CJ, Tatum AH, Jiang F, **Stoll ML**, and Gavalchin J. Molecular identification of pathogenic Id^{LN}F₁ autoantibody idiotypes derived from the (NZB x SWR)F₁ model for Systemic Lupus Erythematosus. *Journal of Autoimmunity* 2002; 19: 87-101.
3. **Stoll ML** and Listman JA. Nephrolithiasis in a neonate with transient renal wasting of calcium and magnesium. *Pediatric Nephrology* 2002; 17: 386-389.
4. Brown K, Ratner M, and **Stoll M**. Pheochromocytoma unmasked by imipramine in an 8-year old girl. *Pediatric Emergency Care* 2003; 19: 174-177.
5. **Stoll ML**, Gauthier BG, Vergara M, Ramek J, Frank R, and Trachtman H. Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF. *Pediatric Nephrology* 2004; 19: 120-121.
6. **Stoll ML** and Rubin LG. Incidence of occult bacteremia among highly febrile young children presenting to a children's hospital emergency department or urgent care center in the era of the pneumococcal conjugate vaccine. *Archives of Pediatric and Adolescent Medicine* 2004; 158: 671-675.

7. **Stoll ML** and Nigrovic PA. Subpopulations within juvenile psoriatic arthritis: A review of the literature. *Clinical and Developmental Immunology* 2006; 13: 377-380.
8. **Stoll ML**, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, and Nigrovic PA. Patients with juvenile psoriatic arthritis comprise two distinct populations. *Arthritis Rheum*, 2006; 54 (11): 3564-3572.
9. **Stoll ML**, Price KD, Silvin CJ, Jiang F, and Gavalchin J. Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR x NZB)F₁ murine model. *Journal of Autoimmunity* 2007; 29(1): 30-37.
10. **Stoll ML**, Lio P, Sundel RP, and Nigrovic PA. Comparison of Vancouver and International League of Associations for Rheumatology classification criteria for juvenile psoriatic arthritis. *Arthritis Care and Research* 2008; 59(1): 51-58.
11. **Stoll ML** and Gotte AC. Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from adult and pediatric experiences. *Biologics: Targets and Therapies* 2008; 2(2): 229-252.
12. **Stoll ML**, Solomon DH, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, and Shadick NA. TNF α Inhibitors May Improve Asthma Symptoms: A Case Series of 12 Patients with Rheumatoid Arthritis and Asthma. *J Clin Rheumatol* 2009; 15(4): 198 – 200.
13. Simard JF, **Stoll ML**, Shadick NA, Karlson EW, Solomon DH. Validity of Self-report of Infections in a Longitudinal Cohort of Patients with Rheumatoid Arthritis Differs by Source of Report and Infection Severity *J Clin Epi*, 2010; 63:1358 – 1362.
14. **Stoll ML**, Bhole R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a Pediatric population: Risk Factors for Sacroiliitis. *J Rheumatol* 2010; 37(11): 2402 – 2408.
15. **Stoll ML**, Interactions of the innate and adaptive arms of the immune system in the pathogenesis of spondyloarthritis. *Clin Exp Rheumatol* 2011; 29: 322 – 330.
16. **Stoll ML**, Nigrovic PA, Gotte AC, and Punaro M. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2011; 29: 582-588.
17. **Stoll ML**, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. *Curr Opin Rheumatol*, 2011; 23: 437-443.
18. **Stoll ML**, Li Q, Zhou J, Punaro M, and Olsen N. Elevated IgG autoantibody production in oligoarticular juvenile idiopathic arthritis may predict a refractory course. *Clin Exp Rheumatol*, 2011; 29: 736 - 742.
19. **Stoll ML**, Patel AS, Punaro M. Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis. *J Rheumatol*, 2011; 38: 2274 - 2275.
20. **Stoll ML**, Patel AS, Punaro M, Dempsey-Robertson M. MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. *Pediatr Rheumatol Online J*, 2012; 10: 6.
21. Feng F, Silvin C, Fiore N, **Stoll M**, Shanley P, Silverstone AE, and Gavalchin J. 17 β -Estradiol (E-2) administration to male (NZB x SWR)F₁ mice results in increased IdLNF₁-reactive memory T-lymphocytes and accelerated glomerulonephritis. *Lupus*, 2012; 21: 288 - 301.
22. **Stoll ML**, Good J, Sharpe T, Beukelman T, Young D, Waite PW, and Cron RQ. Intraarticular corticosteroid injections to the temporomandibular joints are safe and

appear to be effective therapy in children with juvenile idiopathic arthritis. *J Oral Maxillofac Surg*, 2012; 70: 1820 - 1827.

23. DeWitt EM, Kimura Y, Beukelman T, Nigrovic PA, Onel K, Prahalad S, Schneider, R, **Stoll ML**, Angeles-Han S, Milojevic D, Schikler KN, Vehe R, Weiss J, Weiss P, Ilowite N, and Wallace C. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. *Arthritis Care Res*, 2012; 64: 1001 - 1010.
24. **Stoll ML**, Patel AS, Christadoss ML, Punaro M, and Olsen NJ. IgA transglutaminase levels in children with juvenile idiopathic arthritis. *Annals Paediatr Rheumatol*, 2012; 1: 31 – 35.
25. **Stoll ML**, Sharpe T, Beukelman T, Good J, Young D., and Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. *J Rheumatol*, 2012; 39: 1880 - 1887.
26. Nylandk JF, **Stoll ML**, Jiang F, Feng F, and Gvalchin J. Mechanisms involved in the p62-73 idiopeptide-modulated delay of lupus nephritis in SNF1 mice. *Lupus*, 2012; [Epub ahead of print].

Manuscripts in press

27. **Stoll ML**, Morlandt ABP, Terrawattanapong S, Young D, Waite PD, and Cron RQ. Safety and efficacy of intra-articular infliximab therapy for treatment resistant temporomandibular joint arthritis in children: a retrospective study. *Rheumatol (Oxford)*, *in press*.

PUBLISHED ABSTRACTS

Poster presentations

1. Idiotype-induced tolerance in a murine model of SLE. **Stoll ML**, Price K, Silvin CJ, and Gavalchin J. SLE Conference. November 5-8, 1997, National Institutes of Health, Washington, DC: Oral presentation
2. **Stoll ML**, Christadoss ML, Punaro M, and Olsen NJ. MMP-3 and DKK-1 levels in juvenile idiopathic arthritis. *Arthritis and Rheumatism* 2010; 62(10):S621 – 622.
3. **Stoll M**, Punaro M, and Dempsey-Robertson M. Gut inflammation in pediatric spondyloarthritis. *Arthritis and Rheumatism* 2010; 62(10):S94 – 95.

Oral presentations

4. Treatment of female (SWR x NZB)F₁ mice with peptides derived from pathogenic autoantibodies delays the onset of murine lupus. **Stoll ML**, Price K, Silvin CJ, Jiang F, and Gavalchin J. Alpha Omega Alpha Research Conference. March 23, 1999, Upstate Medical University, Syracuse, NY: Oral presentation
5. Are the CBC and blood culture necessary in the evaluation of febrile children 2-36 months of age in the Prevnar era? **Stoll ML** and Rubin L. Nassau Pediatric Society, June 9, 2003, Carle Place, NY: Oral presentation
6. Patients with juvenile psoriatic arthritis comprise two distinct populations. **Stoll ML**, Zurakowski D, Nigrovic LE, Nichols DP, Sundel RP, and Nigrovic PA. Clinical Immunology Society, March 17, 2006. Santa Fe, NM: Oral presentation (Matthew Stoll, presenter)
7. ILAR Criteria for juvenile psoriatic arthritis restrict inclusion without achieving clinical homogeneity. **Stoll ML**, Nigrovic PA, and Sundel RP. American College of Rheumatology, November 14, 2006. Abstract # 2051. Washington, D.C.: Oral presentation (Matthew Stoll, presenter)
8. **Stoll, M.L.**, Morlandt, A.B.P., Terrawattanapong, S., Young, D., Waite, P.D., and Cron, R.Q. 2012. Safety and efficacy of intra-articular infliximab therapy for treatment resistant temporomandibular joint arthritis in children (abstract). *Arthritis Rheum.* 64 (suppl 10):??. [ACR 2012, Washington, DC] [presented as an oral presentation by Dr. Stoll]